Optimizing anti-TNF treatment in inflammatory bowel disease.
about
Promising biological therapies for ulcerative colitis: A review of the literatureClinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updatePharmacogenetics in inflammatory bowel diseaseA new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UCGene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?Reduction of experimental necrotizing enterocolitis with anti-TNF-alphaRole of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.Exploitation of the nicotinic anti-inflammatory pathway for the treatment of epithelial inflammatory diseases.Epithelial barrier: an interface for the cross-communication between gut flora and immune system.Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseAnimal models of colitis-associated carcinogenesis.European evidence based consensus on the diagnosis and management of Crohn's disease: current management.On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patientsPreventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis.Medical management of inflammatory bowel disease among Canadian gastroenterologists.An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease.Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapyAMP-18 Targets p21 to Maintain Epithelial Homeostasis.Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.Guidelines for the management of inflammatory bowel disease in adults.Infliximab in the treatment of Crohn's disease.Biological response modifiers for the treatment of Crohn's disease.Risks and benefits of biologic therapy for inflammatory bowel diseases.Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.Immunopathogenesis of Crohn's disease.Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel diseaseSafety of biologic therapy.Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults.Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).Infliximab therapy for pediatric Crohn's disease.Mechanism of glucocorticoid regulation of the intestinal tight junction barrier.Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitisComparative effects of α2δ-1 ligands in mouse models of colonic hypersensitivity.Advances in the pathogenesis and treatment of IBDRetrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population.Modulation of anti-inflammatory response in lipopolysaccharide stimulated human THP-1 cell line and mouse model at gene expression level with indigenous putative probiotic lactobacilliThalidomide effect in endothelial cell of acute radiation proctitis.Current and future therapies for inflammatory bowel disease.
P2860
Q26776139-89136BC8-4CBC-4D1E-BCDF-A32B4BF1E29DQ26994776-54B7B794-EA33-4031-AB48-BE00064BA48AQ28246002-63BF1D4F-4802-4E16-BF36-008538265296Q28248835-76E2F6E3-A318-4842-ADBC-167D5E71DEF8Q28486322-B562F4D1-C677-4F85-BB01-7B7683434D59Q28572801-088F7EDC-9835-4CBE-AEC3-82FF20281CD0Q30438775-9DCC11A3-89BD-4717-A4CE-8D05ABF19184Q33362566-864B5E12-6548-4CB8-8659-127CD272BEF6Q33574857-6080A27D-B999-43C5-B70A-6A73932284FEQ33866877-F5B0CDEF-2B91-4797-A2D4-00CA8DE0F5A1Q34240555-93F7F753-CA84-46CF-9E7A-B1C63A7F81A2Q34449843-A0C42337-1F94-440E-9B28-A55C94B3D6A6Q34512820-F63EA0D0-1EA5-467A-9A86-AE006A067499Q34564902-9B18DCE9-8E41-4F92-AED4-DF6529D35FAAQ35059648-6E8AFDA1-DEFC-4F92-B5E1-569F3748B75FQ35059717-59E9ADE0-F1BE-4C1C-837D-D819EB60A090Q35505999-74E09859-BE83-4936-BCDF-FFB17FEF7236Q35586236-D83751FC-C8F2-4976-A070-8AB1D00A0803Q35597763-4F90A51E-BE57-446A-A2FD-7CA960901B0BQ35616754-96CF0086-0CD7-4246-AA23-F4A3A122CD38Q35760415-4565F81D-5F3C-412E-A974-A50159247603Q35790559-6503A430-1608-45C7-8ADF-0DEE2EEFE4BFQ35919228-6D96FE2A-3373-423D-BAA6-CA13FCD03FD8Q35925597-B8263CC1-8848-4EA5-896B-6EFBCE1EBF73Q35929544-720354A2-6E8B-41E4-BDF9-4946CBDB2448Q36009845-902457D7-96E6-47A8-AF8A-87216C8F276BQ36175758-26438DA1-5954-481B-9C3F-3E6335DEF2CFQ36330198-5E481B66-559D-4449-823B-E16E79BFC45DQ36737339-B3F4D269-9FBD-43B2-8622-419F4D64BBB7Q36865926-D667460A-B391-4836-8971-3144AC7F4E6AQ36920423-E0D58393-5E6D-4D01-8790-EF9270D2982EQ37012073-EAF9F679-E2B5-4718-96F2-0187CA095171Q37047083-A420CD5F-B048-432A-B68F-719046F3307DQ37164215-522595E8-6A5B-4C5C-A05A-C1EA84E81E2CQ37183034-8807CEB1-E1C4-4BA7-85FF-CB9E742EFEC5Q37219854-6EC31BC3-4318-4523-9004-A4028882097DQ37267284-67552760-A7D9-4137-9356-D434A3A45F0BQ37299999-DEFA2A6B-1D8C-4FBE-AA9E-FDD9052B7982Q37336406-E9B68F82-FD0F-4BAB-8D98-DCB6BC437DE7Q37346047-03EB4F24-FF68-43AA-8A3A-559517E4DF01
P2860
Optimizing anti-TNF treatment in inflammatory bowel disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Optimizing anti-TNF treatment in inflammatory bowel disease.
@ast
Optimizing anti-TNF treatment in inflammatory bowel disease.
@en
type
label
Optimizing anti-TNF treatment in inflammatory bowel disease.
@ast
Optimizing anti-TNF treatment in inflammatory bowel disease.
@en
prefLabel
Optimizing anti-TNF treatment in inflammatory bowel disease.
@ast
Optimizing anti-TNF treatment in inflammatory bowel disease.
@en
P50
P921
P1433
P1476
Optimizing anti-TNF treatment in inflammatory bowel disease.
@en
P304
P356
10.1053/J.GASTRO.2004.02.070
P407
P577
2004-05-01T00:00:00Z